Added Value of Contrast‐Enhanced T1‐Weighted and Diffusion‐Weighted Sequences for Characterization of Incidental Findings on Whole Body Magnetic Resonance Imaging in Plasma‐Cell Disorders
暂无分享,去创建一个
V. Goh | R. Neji | H. Verma | J. Winfield | M. Kazmi | O. Westerland | N. Sivarasan | S. Natas | S. McElroy | I. El-Najjar | M. Streetly | I. El‐Najjar
[1] H. Goldschmidt,et al. Diffusion‐weighted imaging for non‐invasive and quantitative monitoring of bone marrow infiltration in patients with monoclonal plasma cell disease: a comparative study with histology , 2011, British journal of haematology.
[2] M. Galia,et al. Whole-body MRI in patients with lymphoma: collateral findings , 2016, La radiologia medica.
[3] Hans Erik Johnsen,et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. , 2014, The Lancet. Oncology.
[4] H. Völzke,et al. Potentially relevant incidental findings on research whole-body MRI in the general adult population: frequencies and management , 2013, European Radiology.
[5] C. Messiou,et al. Frequency, distribution and clinical management of incidental findings and extramedullary plasmacytomas in whole body diffusion weighted magnetic resonance imaging in patients with multiple myeloma , 2016, Haematologica.
[6] G. Morgan,et al. Whole-body diffusion-weighted MR imaging for assessment of treatment response in myeloma. , 2014, Radiology.
[7] J. Jaremko,et al. Whole-body MRI in neurofibromatosis: incidental findings and prevalence of scoliosis , 2012, Skeletal Radiology.
[8] K. Verstraete,et al. Value of whole body MRI and dynamic contrast enhanced MRI in the diagnosis, follow-up and evaluation of disease activity and extent in multiple myeloma. , 2013, European journal of radiology.
[9] Vicky Goh,et al. Guidelines for the use of imaging in the management of patients with myeloma , 2017, British journal of haematology.